Stockreport

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

ProQR Therapeutics N.V. - Ordinary Shares  (PRQR) 
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: proqr.com
PDF Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials [Read more]